Citigroup
RPRX icon

Citigroup’s Royalty Pharma RPRX Stock Holding History

Citigroup’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.8M Buy
496,398
+35,969
+8% +$1.87M 0.01% 995
2026
Q1 		$22.1M Buy
460,429
+96,202
+26% +$4.21M 0.01% 1008
2025
Q4 		$14.1M Buy
364,227
+110,773
+44% +$4.22M 0.01% 1310
2025
Q3 		$8.94M Sell
253,454
-132,843
-34% -$4.81M ﹤0.01% 1570
2025
Q2 		$13.9M Buy
386,297
+52,407
+16% +$1.74M 0.01% 1176
2025
Q1 		$10.4M Sell
333,890
-23,145
-6% -$734K 0.01% 1341
2024
Q4 		$9.11M Sell
357,035
-171,467
-32% -$4.55M 0.01% 1446
2024
Q3 		$15M Sell
528,502
-66,237
-11% -$1.83M 0.01% 1111
2024
Q2 		$15.7M Buy
594,739
+122,896
+26% +$3.41M 0.01% 1010
2024
Q1 		$14.3M Buy
471,843
+143,850
+44% +$4.24M 0.01% 1052
2023
Q4 		$9.21M Buy
327,993
+48,840
+17% +$1.34M 0.01% 1263
2023
Q3 		$7.58M Buy
279,153
+32,580
+13% +$968K 0.01% 1237
2023
Q2 		$7.58M Buy
246,573
+74,629
+43% +$2.53M 0.01% 1262
2023
Q1 		$6.2M Buy
171,944
+69,140
+67% +$2.56M ﹤0.01% 1378
2022
Q4 		$4.06M Sell
102,804
-20,479
-17% -$855K ﹤0.01% 1571
2022
Q3 		$4.95M Buy
123,283
+8,893
+8% +$380K ﹤0.01% 1572
2022
Q2 		$4.81M Sell
114,390
-39,557
-26% -$1.62M ﹤0.01% 1561
2022
Q1 		$6M Buy
153,947
+37,054
+32% +$1.46M ﹤0.01% 1573
2021
Q4 		$4.66M Sell
116,893
-13,665
-10% -$531K ﹤0.01% 1891
2021
Q3 		$4.72M Buy
130,558
+12,913
+11% +$502K ﹤0.01% 1862
2021
Q2 		$4.82M Sell
117,645
-47,690
-29% -$2.03M ﹤0.01% 1923
2021
Q1 		$7.21M Buy
165,335
+104,955
+174% +$4.98M ﹤0.01% 1572
2020
Q4 		$3.02M Buy
60,380
+22,554
+60% +$957K ﹤0.01% 2474
2020
Q3 		$1.59M Buy
37,826
+37,626
+18,813% +$1.61M ﹤0.01% 2866
2020
Q2 		$10K Buy
+200
New +$9.9K ﹤0.01% 7060

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's RPRX Position: Q2 2026 in Review

Citigroup increased its Royalty Pharma (RPRX) stake by 7.8% in Q2 2026, buying an estimated $1.87M and bringing the position to 496,398 shares worth $27.8M. The position accounts for 0.01% of the portfolio, ranked #995.

Citigroup first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Citigroup held 496,398 shares of Royalty Pharma worth $27.8M as of Q2 2026.
  • Citigroup bought 35,969 Royalty Pharma shares in Q2 2026, an estimated $1.87M.
  • Royalty Pharma made up 0.01% of Citigroup's portfolio in Q2 2026, its #995 holding.
  • Citigroup first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.